

THE LANCET

Child & Adolescent Health

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Nygaard U, Holm M, Hartling UB, et al. Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study. *Lancet Child Adolesc Health* 2022; published online May 5. [https://doi.org/10.1016/S2352-4642\(22\)00100-6](https://doi.org/10.1016/S2352-4642(22)00100-6).

APPENDIX

Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study

Ulrikka Nygaard, Mette Holm, Ulla Birgitte Hartling, Jonathan Glenthøj, Lisbeth Samsø Schmidt, Sannie Brit Nordly, Astrid Thaarup Matthesen, Marie-Louise von Linstow, Laura Espenhain

Page 1

Supplementary Table

Number of MIS-C cases, SARS-CoV-2 infections, and incidence of MIS-C in children and adolescents based on laboratory proven SARS-CoV-2 infections by age group, vaccination status and SARS-CoV-2 variant

Supplementary Table

Number of MIS-C cases, SARS-CoV-2 infections, and incidence of MIS-C in children and adolescents based on laboratory proven SARS-CoV-2 infections by age group, vaccination status and SARS-CoV-2 variant

	MIS-C FOLLOWING THE DELTA VARIANT August 2021 to February 2022				MIS-C FOLLOWING THE WILD TYPE VARIANT March 2020 to February 2021			
	MIS-C	Proven SARS-CoV-2 infections ¹	Incidence of MIS-C following infection		MIS-C	Estimated SARS-CoV-2 infections ²	Incidence of MIS-C following infection	
	N	N	Per 1,000,000 (95% CI)	Incidence of MIS-C	N	N	Per 1,000,000 (95% CI)	Incidence of MIS-C
Not vaccinated								
Total (age 0-17)	51	85,947	593 (442-780)	1:1,700 (1,300-2,300)	23	38,974	590 (374-885)	1:1,700 (1,100-2,700)
0-4	3	10,024	299 (62-874)	1:3,300 (1,100-16,100)	4	5,466	732 (199-1,873)	1:1,400 (500-5,500)
5-11	42	58,863	714 (514-964)	1:1,400 (1,000-1,900)	10	14,029	713 (342-1,311)	1:1,400 (700-2,900)
12-17	6	17,060	352 (129-765)	1:2,800 (1,300-7,800)	9	19,479	462 (211-877)	1:2,200 (1,100-4,700)
Vaccinated³								
12-17	1	6,570	152 (4-848)	1:6,600 (1,200-260,000)				

¹Laboratory confirmed cases of SARS-CoV-2 in the period July 15 to December 15, 2021

²Estimated by serology

³Defined as SARS-CoV-2 infection occurring at least 14 days after the second vaccine dose